ORIC Pharmaceuticals, Inc. (ORIC)
NASDAQ: ORIC · Real-Time Price · USD
9.07
-0.17 (-1.84%)
At close: Nov 2, 2026, 4:00 PM EST
9.23
+0.16 (1.76%)
After-hours: Nov 2, 2026, 5:30 PM EST
ORIC Pharmaceuticals Employees
ORIC Pharmaceuticals had 111 employees as of June 30, 2026. The number of employees decreased by 17 or 13.28% compared to the same quarter last year. That makes ORIC Pharmaceuticals the 30,838th largest employer in the world and 3,940th in the United States.
Employees
111
Change (1Y)
-17
Growth (1Y)
-13.28%
Revenue / Employee
n/a
Profits / Employee
-$1,264,423
Market Cap
940.13M
Employees Chart
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Jun 30, 2026 | 111 | -17 | -13.28% |
| Mar 31, 2026 | 104 | -18 | -14.75% |
| Dec 31, 2025 | 104 | -11 | -9.57% |
| Sep 30, 2025 | 106 | -6 | -5.36% |
| Jun 30, 2025 | 128 | 21 | 19.63% |
| Mar 31, 2025 | 122 | 20 | 19.61% |
| Dec 31, 2024 | 115 | 15 | 15.00% |
| Sep 30, 2024 | 112 | 19 | 20.43% |
| Jun 30, 2024 | 107 | 18 | 20.22% |
| Mar 31, 2024 | 102 | 14 | 15.91% |
| Dec 31, 2023 | 100 | 14 | 16.28% |
| Sep 30, 2023 | 93 | 5 | 5.68% |
| Jun 30, 2023 | 89 | 6 | 7.23% |
| Mar 31, 2023 | 88 | 9 | 11.39% |
| Dec 31, 2022 | 86 | 8 | 10.26% |
| Sep 30, 2022 | 88 | 14 | 18.92% |
| Jun 30, 2022 | 83 | 13 | 18.57% |
| Mar 31, 2022 | 79 | 13 | 19.70% |
| Dec 31, 2021 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Sep 30, 2021 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2021 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2021 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Sep 30, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| Immatics | 704 |
| MeiraGTx Holdings | 393 |
| Kura Oncology | 260 |
| Rigel Pharmaceuticals | 174 |
| Monte Rosa Therapeutics | 173 |
| MoonLake Immunotherapeutics | 130 |
| Cullinan Therapeutics | 109 |
| Odyssey Therapeutics | 100 |
ORIC News
- 6 days ago - Oric Pharmaceuticals price target lowered to $14 from $17 at Wedbush - TheFly
- 6 days ago - Oric Pharmaceuticals selloff on J&J data ‘way overdone,’ says Cantor Fitzgerald - TheFly
- 6 days ago - Oric Pharmaceuticals selloff brings buying opportunity, says Jones - TheFly
- 7 days ago - Oric Pharmaceuticals drops after J&J presents prostate cancer drug data - TheFly
- 7 days ago - Oric Pharmaceuticals price target raised to $18 from $14 at Stifel - TheFly
- 10 days ago - Oric lung cancer data potentially best-in-class, says Jones - TheFly
- 10 days ago - ORIC Pharmaceuticals Transcript: Study update - Transcripts
- 10 days ago - ORIC Pharmaceuticals Press release: Study update - Filings